Competing priorities Sample Clauses

Competing priorities. Participants indicate that they have too many other problems to deal with, such as a water shortage and unemployment, and that those who do attend meetings make requests but “No one comes here to help” (Gondh woman, Mandla). Gendered Participation in JFM Within a given site, there are gender- specific constraints to participation in JFM. In theory, JFM is designed to encourage the representation and participation of women and of different ethnic groups. There are provisions for women on the board of VFCs. In the study villages, women are occupying seats reserved for them (at least 2 seats out of 10 or 11) and Aside from being on the VFC board, the main forum for having a voice in JFM is as a general VFC member. All adult women and men over the age of 18 who pay a symbolic fee are considered members. Most VFCs reportedly meet monthly or bi -monthly for board meetings and annually for the general assembly. Formally influencing the group requires attending, speaking up, and being listened to in VFC meetings, where women are largely outnumbered by men. Opinions about women’s engagement at meetings are mixed, as some participants report that women are listened to and respected, but the majority indicates otherwise. Participants cite numerous barriers to women’s active participation at these meetings, including:
Sample 1Sample 2
AutoNDA by SimpleDocs
Competing priorities. The PRIME will develop a strategic approach for managing multiple competing priorities, specifically the need to “get on” with Modernization yet deferring major systems development until the IRS possesses the requisite capabilities to partner with the private sector. The PRIME will implement approaches and strategies that will facilitate proceeding with modernization, such as: ♦ Providing critical capability building interventions that would allow the IRS to develop the skills to manage a program with the size and complexity of IRS Modernization ♦ Importing proven solutions and focusing on solutions with measurable results, that will allow the PRIME and the IRS to jump start modernization ♦ Linking the PRIME’s organizational development strategy directly to the ELC to ensure the organization builds the partnering management skills it needs throughout the development process
Sample 1

Related to Competing priorities

  • Competing Services Subject to the provisions of this Section 9, and Contractor’s obligations with respect to Confidential Information, including as defined in Section 10, nothing in this Contract precludes or limits in any way the right of Contractor to: (i) provide services similar to those contemplated in this Contract, or consulting or other services of any kind or nature whatsoever to any individual or entity as Contractor in its sole discretion deems appropriate, or (ii) develop for Contractor or for others, Deliverables or other materials that are competitive with those produced as a result of the Services provided hereunder, irrespective of their similarity to the Deliverables delivered pursuant to this Contract. Each party is free to utilize any concepts, processes, know-how, techniques, improvements or other methods it may develop during the course of performance under this Contract free of any use restriction or payment obligation to the other.

  • Geographical Indications 1. Each Party shall recognise that geographical indications may be protected through a trade xxxx or sui generis system or other legal means in accordance with its laws and regulations.

  • Territory 43.1 This Agreement applies to the territory in which Verizon operates as an Incumbent Local Exchange Carrier in the Commonwealth of Pennsylvania. Verizon shall be obligated to provide Services under this Agreement only within this territory.

  • Regulatory Approval 25.1 The Parties understand and agree that this Agreement and any amendment or modification hereto will be filed with the Commission for approval in accordance with Section 252 of the Act and may thereafter be filed with the FCC. The Parties believe in good faith and agree that the services to be provided under this Agreement are in the public interest. Each Party covenants and agrees to fully support approval of this Agreement by the Commission or the FCC under Section 252 of the Act without modification.

  • Licensing Schemes and Geographic Scope The following provisions do not apply to Quintiq Last Mile Edition (5MB-LEQ) nor to Quintiq Last Mile Shipments (for Retail) (5MP-LMQ) nor to Quintiq Last Mile Shipments (for Express) (5MP-LMQ-X). For Quintiq Last Mile Edition (5MB-LEQ), Quintiq Last Mile Shipments (for Retail) (5MP-LMQ) and Quintiq Last Mile Shipments (for Express) (5MP-LMQ-X), please refer to section 5 hereinafter.

  • Geographic Scope The "Territory," which defines the geographic scope of the covenants contained in this Section 7, shall extend to and include all of the states (or foreign equivalent) in which the Company does business as M&A advisors or private placement equity advisors.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • National and Most-favoured-nation Treatment 1. Each Contracting Party shall in its territory accord investments and returns of investors of the other Contracting Party treatment which is fair and equitable and not less favourable than that which it accords to investments and returns of its own investors or to investments and returns of investors of any third State whichever is more favourable.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Regulatory Approvals All Requisite Regulatory Approvals shall have been obtained and shall remain in full force and effect and all statutory waiting periods in respect thereof shall have expired, and no such Requisite Regulatory Approval shall have resulted in the imposition of any Materially Burdensome Regulatory Condition.

Time is Money Join Law Insider Premium to draft better contracts faster.